Osteoporosis remains a significant health concern
for older men in the US and a significant cause
of fracture-related morbidity and mortality. In
addition to age-related bone loss in men, androgen
deprivation therapy for prostatic cancer significantly
increases bone loss, leading to osteoporosis and
an increased incidence of fracture. Because many
patients who are diagnosed with prostate cancer
are elderly, there has been increased concern for
the impact of androgen deprivation therapy on bone
health. Topics
covered in this program
- Explain the risk factors for osteoporosis
in men.
- Describe treatment options for osteoporosis
in men receiving androgen- deprivation therapy
for prostate cancer.
The American Medical Association is accredited by
the Accreditation
Council for Continuing Medical Education (ACCME)
to provide continuing medical education for physicians.
The American Medical Association designates this
module for a maximum of 1.5 AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with
the extent of their participation in the activity.
Nonphysicians may receive a certificate of participation
for completing this activity.
The development of this CME web module was supported
in part through an independent education grant from
the Alliance for Better Bone Health and produced in
accordance with the AMA Standards for Industry-Supported
Multimedia Continuing Medical Education and Other
Communications.
|
